Sage Accounts Payable from 2010 to 2024

SAGE Stock  USD 5.00  0.03  0.60%   
Sage Therapeutic's Accounts Payable is increasing over the years with slightly volatile fluctuation. Overall, Accounts Payable is expected to go to about 11.5 M this year. Accounts Payable is the amount Sage Therapeutic owes to suppliers or vendors for products or services received but not yet paid for. It represents Sage Therapeutic's short-term liabilities. View All Fundamentals
 
Accounts Payable  
First Reported
2012-12-31
Previous Quarter
8.7 M
Current Value
7.1 M
Quarterly Volatility
5.7 M
 
Yuan Drop
 
Covid
Check Sage Therapeutic financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sage Therapeutic's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.3 M, Interest Expense of 17.1 M or Selling General Administrative of 144.2 M, as well as many indicators such as Price To Sales Ratio of 14.25, Dividend Yield of 0.0 or PTB Ratio of 1.7. Sage financial statements analysis is a perfect complement when working with Sage Therapeutic Valuation or Volatility modules.
  
Check out the analysis of Sage Therapeutic Correlation against competitors.
For information on how to trade Sage Stock refer to our How to Trade Sage Stock guide.

Latest Sage Therapeutic's Accounts Payable Growth Pattern

Below is the plot of the Accounts Payable of Sage Therapeutic over the last few years. An accounting item on the balance sheet that represents Sage Therapeutic obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Sage Therapeutic are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Sage Therapeutic's Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sage Therapeutic's overall financial position and show how it may be relating to other accounts over time.
Accounts Payable10 Years Trend
Slightly volatile
   Accounts Payable   
       Timeline  

Sage Accounts Payable Regression Statistics

Arithmetic Mean9,328,316
Geometric Mean5,830,605
Coefficient Of Variation95.06
Mean Deviation6,411,895
Median9,350,000
Standard Deviation8,867,616
Sample Variance78.6T
Range32.7M
R-Value0.53
Mean Square Error61.1T
R-Squared0.28
Significance0.04
Slope1,045,622
Total Sum of Squares1100.9T

Sage Accounts Payable History

202411.5 M
202310.3 M
202218.9 M
202110.4 M
20203.7 M
201915.3 M
201834 M

About Sage Therapeutic Financial Statements

Sage Therapeutic stakeholders use historical fundamental indicators, such as Sage Therapeutic's Accounts Payable, to determine how well the company is positioned to perform in the future. Although Sage Therapeutic investors may analyze each financial statement separately, they are all interrelated. For example, changes in Sage Therapeutic's assets and liabilities are reflected in the revenues and expenses on Sage Therapeutic's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Sage Therapeutic. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Accounts Payable10.3 M11.5 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Sage Therapeutic is a strong investment it is important to analyze Sage Therapeutic's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Sage Therapeutic's future performance. For an informed investment choice regarding Sage Stock, refer to the following important reports:
Check out the analysis of Sage Therapeutic Correlation against competitors.
For information on how to trade Sage Stock refer to our How to Trade Sage Stock guide.
You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sage Therapeutic. If investors know Sage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sage Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(5.57)
Revenue Per Share
1.76
Quarterly Revenue Growth
3.371
Return On Assets
(0.30)
Return On Equity
(0.49)
The market value of Sage Therapeutic is measured differently than its book value, which is the value of Sage that is recorded on the company's balance sheet. Investors also form their own opinion of Sage Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Sage Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sage Therapeutic's market value can be influenced by many factors that don't directly affect Sage Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sage Therapeutic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sage Therapeutic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sage Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.